1. Home
  2. NKLR vs EDIT Comparison

NKLR vs EDIT Comparison

Compare NKLR & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NKLR

Terra Innovatum Global N.V. Ordinary shares

HOLD

Current Price

$6.65

Market Cap

500.6M

Sector

Industrials

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$3.18

Market Cap

526.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKLR
EDIT
Founded
2018
2013
Country
Italy
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
500.6M
526.4M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
NKLR
EDIT
Price
$6.65
$3.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$15.00
$5.30
AVG Volume (30 Days)
362.4K
2.7M
Earning Date
04-01-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.50
EPS
N/A
N/A
Revenue
N/A
$31,937,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
132.64
52 Week Low
$3.73
$1.66
52 Week High
$12.43
$4.54

Technical Indicators

Market Signals
Indicator
NKLR
EDIT
Relative Strength Index (RSI) 58.23 52.98
Support Level $3.94 $2.42
Resistance Level $6.70 $3.27
Average True Range (ATR) 0.49 0.29
MACD 0.04 0.05
Stochastic Oscillator 81.46 46.41

Price Performance

Historical Comparison
NKLR
EDIT

About NKLR Terra Innovatum Global N.V. Ordinary shares

Terra Innovatum Global NV is a micro modular nuclear solutions company that aims to deliver reliable, low-cost and zero-carbon power wherever energy demand is present through its first-of-a-kind reactor SOLO. SOLO is compact yet extremely powerful with one unit generating 1MWe of power, while designed with the strictest safety characteristics and the ability to run 24/7 without the need to refuel for 15 years. Its modular design aims to achieve maximum energy efficiency while significantly reducing the levelized cost of energy (LCOE). SOLO is built using off-the-shelf components and widely available fuel, low-enriched uranium (LEU), which de-risks its regulatory and commercial pathway.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: